Verzenio (abemaciclib tablets) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has recurrent or metastatic breast cancer
• Patient has hormone receptor positive (HR+) [estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)] disease
• Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer AND Verzenio will be used in combination with anastrozole, exemestane, or letrozole OR in combination with fulvestrant OR as monotherapy after progression on at least one prior endocrine therapy AND after chemotherapy for metastatic breast cancer; OR Patient has HER2-positive breast cancer AND has received at least three prior anti-HER2-based regimens in the metastatic setting AND Verzenio will be used in combination with fulvestrant and trastuzumab
• Patient is postmenopausal OR pre/perimenopausal receiving ovarian suppression/ablation with a GnRH agonist OR surgical bilateral oophorectomy or ovarian irradiation

Approval duration

1 year